In summary, these data support the idea of testing HDACi-based combination therapy in patients with 3q26 AML in randomized clinical trials and suggest the use of EVI1 as a potential biomarker of response to epigenetic treatment or resistance to standard of care (Fig. 4H) in patients with EVI1-dependent leukemia. Here, MECOM is linked to acute myeloid leukemia.